The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DNAY | -99.49% | N/A | N/A | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +61% |
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $1.57M | 0.0% |
| Gross Profit | $0.22M | 0.0% |
| Gross Margin | 13.92% | 0.0% |
| Market Cap | $6.79M | 0.0% |
| Market Cap / Employee | $0.17M | 0.0% |
| Employees | 39 | 0.0% |
| Net Income | -$6.18M | 0.0% |
| EBITDA | -$4.35M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $3.82M | 0.0% |
| Accounts Receivable | $1.26M | 0.0% |
| Inventory | 1.1 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.09M | 0.0% |
| Short Term Debt | $2.21M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -67.92% | 0.0% |
| Return On Invested Capital | -60.02% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.01M | 0.0% |
| Operating Free Cash Flow | -$6.96M | 0.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.67 | 55.58 | -0.74 | -0.33 | - |
| Price to Sales | 0.44 | 0.54 | 0.36 | 0.50 | - |
| Price to Tangible Book Value | 8.63 | -2.86 | -0.47 | -0.27 | - |
| Enterprise Value to EBITDA | -11.40 | -8.65 | -6.42 | -11.39 | - |
| Return on Equity | -125.4% | -155.3% | -147.0% | -175.0% | - |
| Total Debt | $34.38M | $36.12M | $35.55M | $16.29M | - |
DNAY earnings call for the period ending June 30, 2022.
DNAY earnings call for the period ending March 31, 2022.
DNAY earnings call for the period ending December 31, 2021.
DNAY earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
